Biohaven is a leader in targeted extracellular protein degradation with its MoDE and TRAP degraders, utilizing ground-breaking science exclusively licensed from Yale. The company announced a restructuring to target a ~60% reduction in annual direct R&D spend while accelerating pivotal trials for degraders and opakalim in 2026.
Cyborg Score Rationale
The company demonstrated strong early clinical data with BHV-1300 showing IgG reductions up to 87%, BHV-1400 showing Gd-IgA1 reductions up to 81%, and opakalim showing seizure reductions ≥50% in most participants. However, BHV-7000 did not meet its primary endpoint in a Phase 2 study for major depressive disorder. The company maintains adequate cash position for clinical development.
Top Insights
Company raised $500.9M in total capital through Q4 2025 and early 2026, with cash and equivalents of $322M as of December 31, 2025, supplemented by $178.9M raised via share offerings in 2026.
In January 2026, Biohaven entered an MoU with King Abdullah University of Science and Technology to collaborate on next-generation degrader development leveraging AI and supercomputing capabilities.
Company is strategically refocusing on key priority areas of immunology, obesity and epilepsy in 2026, discontinuing additional psychiatric trials.
Biohaven has strategic partnerships with Merus N.V., Bristol Myers Squibb, Yale University, and other academic and commercial entities.
Named Competitors
Neurological & Psychiatric Therapies — Neuroscience-focused development stage biotech